Compare UAN & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | SPTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2008 | 2026 |
| Metric | UAN | SPTX |
|---|---|---|
| Price | $135.38 | $23.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.6K | ★ 121.8K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $86.43 | $17.59 |
| 52 Week High | $139.50 | $28.38 |
| Indicator | UAN | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.00 | 48.16 |
| Support Level | $120.76 | $18.72 |
| Resistance Level | $139.42 | $28.38 |
| Average True Range (ATR) | 2.55 | 2.22 |
| MACD | 0.76 | -0.38 |
| Stochastic Oscillator | 92.51 | 20.95 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.